Hereditary Angioedema (HAE) Initiative

Hereditary Angioedema (HAE) is a rare, genetic disorder characterized by recurrent episodes of severe swelling (angioedema) in various parts of the body, including the skin, gastrointestinal tract, upper airway, and limbs. Unlike typical allergic reactions, HAE is not caused by histamine release and does not respond to standard allergy treatments like antihistamines or corticosteroids.

HAE is most commonly caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a protein that helps regulate inflammation and the immune response. The deficiency leads to uncontrolled activation of the bradykinin pathway, which increases vascular permeability and results in fluid leaking into surrounding tissues, causing swelling. HAE is inherited in an autosomal dominant manner, meaning only one copy of the defective gene is sufficient to cause the disorder.

Symptoms often begin in childhood or adolescence and can worsen over time. Swelling attacks may last for several days and can be extremely painful, especially when affecting the abdomen. Swelling of the airway can be life-threatening if not treated promptly. Unlike other types of angioedema, HAE is not accompanied by hives.

Diagnosis involves blood tests to measure levels and function of C1-INH and complement proteins. Early and accurate diagnosis is critical to prevent complications and improve quality of life.

There is no cure for HAE, but several effective treatments are available. These include C1-INH replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors to prevent or treat acute attacks. With proper management, individuals with HAE can lead full, active lives.

Research Progress

.

The Open Science Institute’s Hereditary Angioedema (HAE) Initiative has now progressed to the First phase — Systems Architecture.

We need your support to move forward. Our goal is to raise $2 Million to research and reveal to the scientific community, highlighting the powerful potential of ingredients on HAE. Please support this initiative.

Systems Architecture

The Systems Architecture of Hereditary Angioedema (HAE) is published as a Web-based tool open to public. Click below to interact with the systems architecture

Publication

A peer-reviewed publication from the Hereditary Angioedema (HAE) Initiative will be released soon to benefit the public by revealing powerful insights into the use of compounds for treating Hereditary Angioedema (HAE)—support this initiative to advance scientific discovery and deliver real solutions.

In silico Modeling

In this phase, the Hereditary Angioedema (HAE) Initiative will conduct in silico modeling to identify and test the efficacy of compounds on C1-inhibitor deficiency, Complement system activation and Bradykinin production activity. This phase is yet to begin.

Combination Screening

Patents

The Open Science Institute® through its Hereditary Angioedema (HAE) initiative is moving towards getting patents for a revolutionary compounds that affects C1-inhibitor deficiency, Complement system activation and Bradykinin production activity.

Licensing and Manufacturing

The Hereditary Angioedema (HAE) Initiative plans to discover, develop, license and manufacture a HAE product which supports treatment of many diseases. Support our mission to bring this innovation to those who need it most. Please support this Phase by donating to the Hereditary Angioedema (HAE) Initiative